about
Practical approach to treating essential thrombocythaemia: case studiesCT and MR imaging in Hodgkin's disease--present and future.The role of ifosfamide in the treatment of relapsed and refractory lymphoma.Epidemiology and pathophysiology of immune thrombocytopenic purpura.New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.Emerging strategies to treat chronic immune thrombocytopenic purpura.Immune thrombocytopenic purpura: epidemiology and implications for patients.Characteristics of immune thrombocytopenic purpura: a guide for clinical practice.Immune thrombocytopenic purpura: the treatment paradigm.Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.Heating of the specimen to 37 degrees C does not improve the platelet count.G- and GM-CSF in oncology and oncological haematology.Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994.An epidemiological study of aplastic anaemia: relationship of drug exposures to clinical features and outcome.Immune mechanisms leading to drug-induced blood dyscrasias.High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience.Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience.Drugs in the aetiology of agranulocytosis and aplastic anaemia.Pathogenesis of Hodgkin's lymphoma.Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region.Special issues in pediatric Hodgkin's disease.Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseases.Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT).The radiotherapy reference panel--experiences and results of the German Hodgkin Study Group (GHSG).Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?Clinical trials in North America.Current treatment strategies of the German Hodgkin Study Group (GHSG).The EORTC strategy in the treatment of Hodgkin's lymphoma.Autologous transplantation in relapsed and refractory Hodgkin's disease.The role of allogeneic stem-cell transplantation in Hodgkin's disease.Developing new drugs for the treatment of lymphoma.Immunotherapy of Hodgkin's lymphoma.Aclarubicin: preclinical and clinical data suggesting less chronic cardiotoxicity compared with conventional anthracyclines.Standardization and harmonization of the blood count: the role of International Committee for Standardization in Haematology (ICSH).The therapeutic use of rituximab in non-Hodgkin's lymphoma.Advances in the understanding and management of myeloproliferative disorders.Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.Phenotype and genotype in the myeloproliferative disorders.Myelofibrosis: biology and treatment options.
P1433
Q28220421-560F0976-F0D6-41EF-B6D3-2B512279FDC7Q30993841-6F43908C-09FD-4F64-B365-1746E8D3712BQ33338411-B95478F1-2953-4F49-9088-E3DD388F39C5Q33378367-1790DD04-03DA-43C4-AD3C-A7510F39636CQ33378370-F4CB5566-3AC9-4665-8ED5-C5C04AEB9205Q33378373-EE9B8E6C-4893-43D9-8E10-071174812DECQ33378375-AF9FAC21-1F16-4EFB-A2A5-041AB80BF081Q33383182-CA6F74F6-D348-4A23-A816-7A36D4FCDC8AQ33383184-D0EAAEF7-B89E-44C2-9FC4-5E82C716A6DBQ33383187-689437A0-5A1F-43D6-8A60-7C189ABB0514Q33383188-F90F5BC5-E2F9-45D3-A638-AE390546FE39Q33393798-5A9A339F-6322-46E4-9B30-031579BF07E2Q33487910-64865CBA-8B5B-43A6-A4FF-F255B32F139DQ33498160-014DE159-0AF1-417D-98EB-A4D834A36877Q33498162-DED879DD-7861-41E6-BE8C-1985E8F0B28AQ33498164-0668BB08-8CEB-4CDA-9DB6-738FC0F5AB9CQ34326592-43598BB6-F682-488A-8490-61B02115F756Q34326598-25EE9F0E-1D92-4C1C-9051-644F520159C4Q34412712-B50B08A0-17DF-4E3A-AEED-B686ADA86A78Q36188971-4CF79CC6-4346-4777-BCFF-CEA3B8394244Q36188976-7CA5F495-9279-4C25-8757-B5CCC8686199Q36188980-2CF0A7C0-5DB3-4C70-AE4B-D1D0F5A6C767Q36188986-5B596098-FEEB-46E6-9E48-26D5033E3EE1Q36188990-A172D904-A0AD-46B1-8DDB-D6603AA5F54BQ36188995-6817E617-68DE-4B2B-9714-89528A8ABBF8Q36189000-2B29CC55-0A62-4163-8CB9-507263BB400DQ36189005-87D3F743-961C-4CFC-9B49-1D9CA48BB09CQ36189012-F58F34BE-EA53-4041-A006-1B256A838BB8Q36189017-6D886BC2-66BD-438D-8C48-59F78193DC07Q36189021-350176C3-A0E2-4CCD-B543-2B7D12802909Q36189024-0155BDCD-931E-4205-8153-0C46F1BE0809Q36189028-C2F4775F-DC9C-44CE-8081-062E94B3EF1DQ36189032-28E9FE5D-2185-4D8A-91DD-D0F87D161589Q36464346-5B2473EF-434A-46C7-8DD2-1DFE1DCB3B37Q36622811-8CDC76CB-05E2-4EDD-85F1-2C3B81BA122EQ36700912-2C679A40-31D3-4C59-8A04-DC972E71219EQ36922481-B65D2969-B7EC-4018-AE95-75EBE080C07EQ36922485-A11C822A-D649-454B-9D6C-31FDCDD4BAD5Q36922489-47C2D0EB-F458-4078-940E-8DAE3FAE0A0FQ36922494-C86128E9-1C24-4EAA-915D-9698875A28D2
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Wiley-Blackwell
@nl
wissenschaftliche Fachzeitschrift
@de
name
European journal of haematology. Supplementum
@ast
European journal of haematology. Supplementum
@en
European journal of haematology. Supplementum
@es
European journal of haematology. Supplementum
@it
European journal of haematology. Supplementum
@nl
type
label
European journal of haematology. Supplementum
@ast
European journal of haematology. Supplementum
@en
European journal of haematology. Supplementum
@es
European journal of haematology. Supplementum
@it
European journal of haematology. Supplementum
@nl
altLabel
Eur J Haematol Suppl
@en
prefLabel
European journal of haematology. Supplementum
@ast
European journal of haematology. Supplementum
@en
European journal of haematology. Supplementum
@es
European journal of haematology. Supplementum
@it
European journal of haematology. Supplementum
@nl
P1055
P1156
P123
P1476
European journal of haematology. Supplementum
@en